Pediatric Depression Medications: Zoloft, Paxil & Wellbutrin
This paper examines three pharmacological decision pathways for treating major depressive disorder in an 8-year-old African American male who presents with sadness, irritability, and decreased appetite confirmed by the Children's Depression Rating Scale. Each pathway—Zoloft (sertraline), Paxil (paroxetine), and Wellbutrin (bupropion)—is evaluated across three sequential decision points, tracking initial dosing rationale, observed clinical outcomes, and subsequent dose adjustments. The analysis considers age-appropriate dosing, SSRI tolerability, side effect profiles, and the potential need to switch medications when therapeutic targets are not met or adverse effects emerge.
- Introduction and Clinical Background: 8-year-old patient presenting with depression symptoms
- Zoloft (Sertraline) Decision Points: Sertraline dosage titration across three visits
- Paxil (Paroxetine) Decision Points: Paroxetine trial with side effect complications
- Wellbutrin (Bupropion) Decision Points: Bupropion dosing adjusted for insomnia and efficacy
- Conclusion: Summary of iterative pediatric medication decision-making
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each medication section follows a consistent three-decision-point framework, making it easy to compare pharmacological reasoning across drug choices.
- The paper grounds every dosage decision in clinical rationale, citing the client's age, symptom response, and published literature — demonstrating evidence-based practice.
- Side effect management (nausea with Paxil, insomnia with Wellbutrin) is addressed explicitly, showing awareness of real-world adherence barriers.
Key academic technique demonstrated
The paper uses a sequential clinical decision-making structure in which each outcome directly informs the next intervention. This technique — sometimes called iterative titration reasoning — mirrors actual prescribing practice and allows the writer to justify incremental changes by referencing prior results rather than restating general pharmacology.
Structure breakdown
The paper opens with a brief clinical vignette establishing the patient profile, then divides into three parallel drug sections (Zoloft, Paxil, Wellbutrin), each subdivided into three decision points (initial prescription, response-based adjustment, further adjustment). Each decision point follows the pattern: rationale → expected outcome → actual result → next step. A reference list in APA format closes the paper.
Introduction and Clinical Background
The client in this scenario is an 8-year-old African American male who presents with signs of depression. Reported symptoms include feelings of sadness, occasional irritability, and decreased appetite. The score obtained upon administration of the Children's Depression Rating Scale indicates significant depression. This paper examines three sequential medication decision pathways — Zoloft (sertraline), Paxil (paroxetine), and Wellbutrin (bupropion) — each evaluated across three clinical decision points.
Zoloft (Sertraline) Decision Points
Studies conducted in the past have indicated that for children and adolescents suffering from depression, Zoloft (sertraline) is largely effective. According to Hritzak and Culhane (2004), "Sertraline (Zoloft) is effective and generally well tolerated for the short-term treatment of major depressive disorder in both children and adolescents" (p. 17). Sertraline is an SSRI (selective serotonin reuptake inhibitor) that acts on unbalanced brain chemicals in persons suffering from anxiety disorders, panic disorders, and depression. Low serotonin levels are often responsible for depression, and Zoloft helps restore serotonin balance in the brain.
A dose of 25 mg daily was selected because the client is an 8-year-old; 50 mg daily is the standard dose for adults. The lower starting dose also allowed for upward titration over time as needed. A favorable change in depressive symptoms was expected by the next appointment.
The results of Decision Point 1 indicate that when the client returned to the clinic after 4 weeks, there was no change in depressive symptoms, suggesting that the 25 mg daily dose was insufficient.
The decision to increase the dosage was based on the client's lack of progress. Depressive symptoms had not changed at all. The client's age was still taken into consideration when selecting 37.5 mg orally per day rather than jumping directly to 50 mg once daily. A favorable change of 20–25% in depressive symptoms was expected by the next visit.
The results of Decision Point 2 indicate a 20% decrease in depressive symptoms, and the client reported feeling somewhat better. This improvement can be attributed to the dosage increase from 25 mg to 37.5 mg orally per day. As noted, the initial lower starting dose was deliberately chosen to allow for upward titration over time to the maximum dose depending on outcomes.
The decision to increase the dosage further was based on the results of Decision Point 2, where the prior increase had yielded a 20% reduction in depressive symptoms. A 40–50% decrease in depressive symptoms was expected by the next visit.
The results of Decision Point 3 indicate that there has not been sufficient further reduction in depressive symptoms. At this point, introducing another SSRI would be appropriate, given that the current SSRI has not produced significant symptom reduction. This approach is supported by guidance from the American Academy of Pediatrics (2020): "switching from one SSRI to another can be staggered and overlapping, as long as the combined total daily dose remains equivalent and comparable… a staggered switch can usually be completed over a few weeks."
Paxil (Paroxetine) Decision Points
Paxil (paroxetine), also an SSRI, is used in the treatment of depression due to its action of increasing brain serotonin levels. However, important concerns exist regarding this drug. As Mullen (2018) notes, "paroxetine is useful for severe anxiety but carries the risk of increased suicidality compared with other SSRIs and increased sedation in the pediatric and young adult population" (p. 278). For this reason, close monitoring for changes in the client's symptoms or mood was planned, and a low starting dose was selected.
Upon return to the clinic after 4 weeks, the results of Decision Point 1 showed a reduction of 5 points on the Children's Depression Rating Scale overall, but the client reported complaints of nausea, vomiting, and diarrhea. Although a more significant reduction in depression severity had been expected, the side effects were a concern. Navels, Gentkovsky, and Williams (2016) note that "common side effects associated with paroxetine are sleepiness, yawning, dry mouth, headache, upset stomach/nausea, mild mental fogginess, dizziness, appetite loss, weight gain, nervousness and occasional jitters, delayed ejaculation, and anorgasmia" (p. 83). Given these side effects, it was considered prudent to decrease the dose temporarily before readjusting it upward in an attempt to reduce the adverse effects.
The goal of this decision was to eliminate or reduce the severity of the side effects without compromising the therapeutic gains achieved thus far.
The results of Decision Point 2 indicate that following dose reduction, the side effects subsided. However, once the original dosage was reinstated, the side effects returned. It became clear at this point that the intended therapeutic outcomes may not be achievable due to the unfavorable side effect profile.
As Fainzang (2011) highlights, adverse side effects can affect or limit patient adherence to a treatment regimen. Given the recurring side effects experienced by this client upon reinstatement of paroxetine, switching to a different SSRI was the most appropriate next step.
Conclusion
Across all three medication pathways, dosing decisions were guided by the client's age, symptom response, and tolerability. Each pathway illustrates how iterative titration and a willingness to switch agents are central to effective pediatric depression management. Sertraline showed gradual symptom improvement with dose escalation, though full therapeutic targets were not met, prompting consideration of an alternative SSRI. Paroxetine produced modest symptom relief but persistent gastrointestinal side effects that undermined adherence. Bupropion addressed the dopaminergic mechanism of depression but required a formulation change to manage insomnia before further dose escalation could be pursued. Collectively, these three cases underscore the importance of age-appropriate, evidence-based prescribing practices in child and adolescent psychiatry, where therapeutic goals must always be balanced against safety and tolerability concerns.
Create your account
Always verify citation format against your institution’s current style guide requirements.